Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.9%

1 terminated/withdrawn out of 107 trials

Success Rate

91.7%

+5.2% vs industry average

Late-Stage Pipeline

17%

18 trials in Phase 3/4

Results Transparency

9%

1 of 11 completed trials have results

Key Signals

28 recruiting1 with results

Enrollment Performance

Analytics

N/A
21(31.3%)
Phase 2
20(29.9%)
Phase 3
13(19.4%)
Phase 1
7(10.4%)
Phase 4
5(7.5%)
Early Phase 1
1(1.5%)
67Total
N/A(21)
Phase 2(20)
Phase 3(13)
Phase 1(7)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (107)

Showing 20 of 107 trials
NCT05491811Phase 2Active Not Recruiting

Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation

Role: collaborator

NCT07539753Phase 2Not Yet Recruiting

Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases

Role: collaborator

NCT05449067Not ApplicableCompleted

Nocturnal APD vs. CAPD in Non-diabetic ESKD

Role: collaborator

NCT02633202Phase 3Completed

Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era

Role: collaborator

NCT05523245Recruiting

Predicting the Efficacy of Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer Using an AI Platform Based on Multi-parametric MRI

Role: collaborator

NCT07177794Phase 3Recruiting

Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC

Role: collaborator

NCT05787522Completed

Clinical Validation of AI-Assisted Radiotherapy Contouring Software for Thoracic Organs at Risk

Role: collaborator

NCT06647732Phase 2Recruiting

Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)

Role: collaborator

NCT07323381Phase 4Not Yet Recruiting

Effects of Henagliflozin Proline and Metformin XR on Body Composition in Geriatric Patients With Newly Diagnosed T2DM

Role: collaborator

NCT07188584Phase 3Recruiting

Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer

Role: collaborator

NCT07258108Phase 2Not Yet Recruiting

Lucentis Plus Tagolimumab in PD-L1+, HR+/HER2- Advanced Breast Cancer After CDK4/6 Inhibitors

Role: collaborator

NCT07170345Recruiting

Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion

Role: collaborator

NCT03387774Phase 3Completed

Efficacy of Ulinastatin for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients

Role: collaborator

NCT03636607Not ApplicableWithdrawn

Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions of Primary Hepatocellular Carcinoma

Role: lead

NCT06060782Phase 1Recruiting

Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine

Role: lead

NCT06831357Recruiting

Development and Validation of a Deep Learning Model to Predict Distant Metastases in Nasopharyngeal Carcinoma Using Whole Slide Imaging and MRI

Role: collaborator

NCT05984511Not ApplicableRecruiting

TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT

Role: collaborator

NCT06787456Active Not Recruiting

"Xijiang Project" Screening Cohort for NPC

Role: collaborator

NCT06763289Recruiting

Comparison of Multi-omics Models for Early Nasopharyngeal Carcinoma Screening: CfDNA Methylation, EBV DNA, and Serological Double-antibodies Detection

Role: collaborator

NCT06757894Phase 2Not Yet Recruiting

Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma

Role: collaborator